Logan Capital Management Inc. Trims Stake in Zoetis Inc. (NYSE:ZTS)

Logan Capital Management Inc. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 8.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 91,539 shares of the company’s stock after selling 8,664 shares during the quarter. Logan Capital Management Inc.’s holdings in Zoetis were worth $14,914,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC lifted its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the period. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC purchased a new position in Zoetis in the fourth quarter valued at about $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis during the fourth quarter valued at about $44,000. Finally, Asset Planning Inc bought a new stake in shares of Zoetis in the 4th quarter valued at about $58,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ZTS. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Stifel Nicolaus lowered their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $212.13.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 over the last three months. Company insiders own 0.18% of the company’s stock.

Zoetis Trading Down 1.1%

Shares of Zoetis stock opened at $159.96 on Monday. The stock’s 50 day simple moving average is $157.27 and its 200-day simple moving average is $165.95. The stock has a market cap of $71.37 billion, a P/E ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the prior year, the company posted $1.38 earnings per share. Zoetis’s revenue for the quarter was up 1.4% compared to the same quarter last year. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.